カテゴリー： Market Monitor Global, 世界, 医療/バイオ

グルタミン酸拮抗薬の世界市場見通し2023年-2029年

◆英語タイトル：Glutamate Antagonist Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23FB2476）◆商品コード：MMG23FB2476
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年2月
◆ページ数：71
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界のグルタミン酸拮抗薬市場規模と予測を収録しています。・世界のグルタミン酸拮抗薬市場：売上、2018年-2023年、2024年-2029年
・世界のグルタミン酸拮抗薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のグルタミン酸拮抗薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「イオン性」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

グルタミン酸拮抗薬のグローバル主要企業は、Artemis Neuroscience、VistaGen Therapeutics、Rottapharm Madaus、Amorsa Therapeutics、Newron Pharmaceuticals、Purdue Biopharma、Relmada Therapeutics、BioCrea GmbH、Cerecor Inc.、NeurOp Inc.、UCB SA、Novartis AG、Luc Therapeutics Inc.、Evotec AGなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、グルタミン酸拮抗薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のグルタミン酸拮抗薬市場：タイプ別、2018年-2023年、2024年-2029年
世界のグルタミン酸拮抗薬市場：タイプ別市場シェア、2022年
・イオン性、非イオン性

世界のグルタミン酸拮抗薬市場：用途別、2018年-2023年、2024年-2029年
世界のグルタミン酸拮抗薬市場：用途別市場シェア、2022年
・病院、診療所、研究所、その他

世界のグルタミン酸拮抗薬市場：地域・国別、2018年-2023年、2024年-2029年
世界のグルタミン酸拮抗薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるグルタミン酸拮抗薬のグローバル売上、2018年-2023年
・主要企業におけるグルタミン酸拮抗薬のグローバル売上シェア、2022年
・主要企業におけるグルタミン酸拮抗薬のグローバル販売量、2018年-2023年
・主要企業におけるグルタミン酸拮抗薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Artemis Neuroscience、VistaGen Therapeutics、Rottapharm Madaus、Amorsa Therapeutics、Newron Pharmaceuticals、Purdue Biopharma、Relmada Therapeutics、BioCrea GmbH、Cerecor Inc.、NeurOp Inc.、UCB SA、Novartis AG、Luc Therapeutics Inc.、Evotec AG

*************************************************************

・調査・分析レポートの概要
グルタミン酸拮抗薬市場の定義
市場セグメント
世界のグルタミン酸拮抗薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のグルタミン酸拮抗薬市場規模
世界のグルタミン酸拮抗薬市場規模：2022年 VS 2029年
世界のグルタミン酸拮抗薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのグルタミン酸拮抗薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のグルタミン酸拮抗薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：イオン性、非イオン性
グルタミン酸拮抗薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、研究所、その他
グルタミン酸拮抗薬の用途別グローバル売上・予測

・地域別市場分析
地域別グルタミン酸拮抗薬市場規模 2022年と2029年
地域別グルタミン酸拮抗薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Artemis Neuroscience、VistaGen Therapeutics、Rottapharm Madaus、Amorsa Therapeutics、Newron Pharmaceuticals、Purdue Biopharma、Relmada Therapeutics、BioCrea GmbH、Cerecor Inc.、NeurOp Inc.、UCB SA、Novartis AG、Luc Therapeutics Inc.、Evotec AG
...

Glutamate Antagonists work by inhibiting the activity of glutamate receptors in the brain. These receptors are broadly classified into two main subtypes: N-methyl-D-aspartate (NMDA) and 3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors.
This report aims to provide a comprehensive presentation of the global market for Glutamate Antagonist, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glutamate Antagonist. This report contains market size and forecasts of Glutamate Antagonist in global, including the following market information:
Global Glutamate Antagonist Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Glutamate Antagonist Market Sales, 2018-2023, 2024-2029, (Units)
Global top five Glutamate Antagonist companies in 2022 (%)
The global Glutamate Antagonist market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Ionic Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Glutamate Antagonist include Artemis Neuroscience, VistaGen Therapeutics, Rottapharm Madaus, Amorsa Therapeutics, Newron Pharmaceuticals, Purdue Biopharma, Relmada Therapeutics, BioCrea GmbH and Cerecor Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Glutamate Antagonist manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
[Total Market by Segment]
Global Glutamate Antagonist Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Glutamate Antagonist Market Segment Percentages, by Type, 2022 (%)
Ionic
Non Ionic
Global Glutamate Antagonist Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Glutamate Antagonist Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Laboratory
Others
Global Glutamate Antagonist Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Glutamate Antagonist Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Glutamate Antagonist revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Glutamate Antagonist revenues share in global market, 2022 (%)
Key companies Glutamate Antagonist sales in global market, 2018-2023 (Estimated), (Units)
Key companies Glutamate Antagonist sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Artemis Neuroscience
VistaGen Therapeutics
Rottapharm Madaus
Amorsa Therapeutics
Newron Pharmaceuticals
Purdue Biopharma
Relmada Therapeutics
BioCrea GmbH
Cerecor Inc.
NeurOp Inc.
UCB SA
Novartis AG
Luc Therapeutics Inc.
Evotec AG
Outline of Major Chapters:
Chapter 1: Introduces the definition of Glutamate Antagonist, market overview.
Chapter 2: Global Glutamate Antagonist market size in revenue and volume.
Chapter 3: Detailed analysis of Glutamate Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Glutamate Antagonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Glutamate Antagonist capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Glutamate Antagonist Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Glutamate Antagonist Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Glutamate Antagonist Overall Market Size
2.1 Global Glutamate Antagonist Market Size: 2022 VS 2029
2.2 Global Glutamate Antagonist Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Glutamate Antagonist Sales: 2018-2029
3 Company Landscape
3.1 Top Glutamate Antagonist Players in Global Market
3.2 Top Global Glutamate Antagonist Companies Ranked by Revenue
3.3 Global Glutamate Antagonist Revenue by Companies
3.4 Global Glutamate Antagonist Sales by Companies
3.5 Global Glutamate Antagonist Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Glutamate Antagonist Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Glutamate Antagonist Product Type
3.8 Tier 1, Tier 2 and Tier 3 Glutamate Antagonist Players in Global Market
3.8.1 List of Global Tier 1 Glutamate Antagonist Companies
3.8.2 List of Global Tier 2 and Tier 3 Glutamate Antagonist Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Glutamate Antagonist Market Size Markets, 2022 & 2029
4.1.2 Ionic
4.1.3 Non Ionic
4.2 By Type – Global Glutamate Antagonist Revenue & Forecasts
4.2.1 By Type – Global Glutamate Antagonist Revenue, 2018-2023
4.2.2 By Type – Global Glutamate Antagonist Revenue, 2024-2029
4.2.3 By Type – Global Glutamate Antagonist Revenue Market Share, 2018-2029
4.3 By Type – Global Glutamate Antagonist Sales & Forecasts
4.3.1 By Type – Global Glutamate Antagonist Sales, 2018-2023
4.3.2 By Type – Global Glutamate Antagonist Sales, 2024-2029
4.3.3 By Type – Global Glutamate Antagonist Sales Market Share, 2018-2029
4.4 By Type – Global Glutamate Antagonist Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Glutamate Antagonist Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Laboratory
5.1.5 Others
5.2 By Application – Global Glutamate Antagonist Revenue & Forecasts
5.2.1 By Application – Global Glutamate Antagonist Revenue, 2018-2023
5.2.2 By Application – Global Glutamate Antagonist Revenue, 2024-2029
5.2.3 By Application – Global Glutamate Antagonist Revenue Market Share, 2018-2029
5.3 By Application – Global Glutamate Antagonist Sales & Forecasts
5.3.1 By Application – Global Glutamate Antagonist Sales, 2018-2023
5.3.2 By Application – Global Glutamate Antagonist Sales, 2024-2029
5.3.3 By Application – Global Glutamate Antagonist Sales Market Share, 2018-2029
5.4 By Application – Global Glutamate Antagonist Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Glutamate Antagonist Market Size, 2022 & 2029
6.2 By Region – Global Glutamate Antagonist Revenue & Forecasts
6.2.1 By Region – Global Glutamate Antagonist Revenue, 2018-2023
6.2.2 By Region – Global Glutamate Antagonist Revenue, 2024-2029
6.2.3 By Region – Global Glutamate Antagonist Revenue Market Share, 2018-2029
6.3 By Region – Global Glutamate Antagonist Sales & Forecasts
6.3.1 By Region – Global Glutamate Antagonist Sales, 2018-2023
6.3.2 By Region – Global Glutamate Antagonist Sales, 2024-2029
6.3.3 By Region – Global Glutamate Antagonist Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Glutamate Antagonist Revenue, 2018-2029
6.4.2 By Country – North America Glutamate Antagonist Sales, 2018-2029
6.4.3 US Glutamate Antagonist Market Size, 2018-2029
6.4.4 Canada Glutamate Antagonist Market Size, 2018-2029
6.4.5 Mexico Glutamate Antagonist Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Glutamate Antagonist Revenue, 2018-2029
6.5.2 By Country – Europe Glutamate Antagonist Sales, 2018-2029
6.5.3 Germany Glutamate Antagonist Market Size, 2018-2029
6.5.4 France Glutamate Antagonist Market Size, 2018-2029
6.5.5 U.K. Glutamate Antagonist Market Size, 2018-2029
6.5.6 Italy Glutamate Antagonist Market Size, 2018-2029
6.5.7 Russia Glutamate Antagonist Market Size, 2018-2029
6.5.8 Nordic Countries Glutamate Antagonist Market Size, 2018-2029
6.5.9 Benelux Glutamate Antagonist Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Glutamate Antagonist Revenue, 2018-2029
6.6.2 By Region – Asia Glutamate Antagonist Sales, 2018-2029
6.6.3 China Glutamate Antagonist Market Size, 2018-2029
6.6.4 Japan Glutamate Antagonist Market Size, 2018-2029
6.6.5 South Korea Glutamate Antagonist Market Size, 2018-2029
6.6.6 Southeast Asia Glutamate Antagonist Market Size, 2018-2029
6.6.7 India Glutamate Antagonist Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Glutamate Antagonist Revenue, 2018-2029
6.7.2 By Country – South America Glutamate Antagonist Sales, 2018-2029
6.7.3 Brazil Glutamate Antagonist Market Size, 2018-2029
6.7.4 Argentina Glutamate Antagonist Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Glutamate Antagonist Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Glutamate Antagonist Sales, 2018-2029
6.8.3 Turkey Glutamate Antagonist Market Size, 2018-2029
6.8.4 Israel Glutamate Antagonist Market Size, 2018-2029
6.8.5 Saudi Arabia Glutamate Antagonist Market Size, 2018-2029
6.8.6 UAE Glutamate Antagonist Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Artemis Neuroscience
7.1.1 Artemis Neuroscience Company Summary
7.1.2 Artemis Neuroscience Business Overview
7.1.3 Artemis Neuroscience Glutamate Antagonist Major Product Offerings
7.1.4 Artemis Neuroscience Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.1.5 Artemis Neuroscience Key News & Latest Developments
7.2 VistaGen Therapeutics
7.2.1 VistaGen Therapeutics Company Summary
7.2.2 VistaGen Therapeutics Business Overview
7.2.3 VistaGen Therapeutics Glutamate Antagonist Major Product Offerings
7.2.4 VistaGen Therapeutics Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.2.5 VistaGen Therapeutics Key News & Latest Developments
7.3 Rottapharm Madaus
7.3.1 Rottapharm Madaus Company Summary
7.3.2 Rottapharm Madaus Business Overview
7.3.3 Rottapharm Madaus Glutamate Antagonist Major Product Offerings
7.3.4 Rottapharm Madaus Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.3.5 Rottapharm Madaus Key News & Latest Developments
7.4 Amorsa Therapeutics
7.4.1 Amorsa Therapeutics Company Summary
7.4.2 Amorsa Therapeutics Business Overview
7.4.3 Amorsa Therapeutics Glutamate Antagonist Major Product Offerings
7.4.4 Amorsa Therapeutics Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.4.5 Amorsa Therapeutics Key News & Latest Developments
7.5 Newron Pharmaceuticals
7.5.1 Newron Pharmaceuticals Company Summary
7.5.2 Newron Pharmaceuticals Business Overview
7.5.3 Newron Pharmaceuticals Glutamate Antagonist Major Product Offerings
7.5.4 Newron Pharmaceuticals Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.5.5 Newron Pharmaceuticals Key News & Latest Developments
7.6 Purdue Biopharma
7.6.1 Purdue Biopharma Company Summary
7.6.2 Purdue Biopharma Business Overview
7.6.3 Purdue Biopharma Glutamate Antagonist Major Product Offerings
7.6.4 Purdue Biopharma Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.6.5 Purdue Biopharma Key News & Latest Developments
7.7 Relmada Therapeutics
7.7.1 Relmada Therapeutics Company Summary
7.7.2 Relmada Therapeutics Business Overview
7.7.3 Relmada Therapeutics Glutamate Antagonist Major Product Offerings
7.7.4 Relmada Therapeutics Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.7.5 Relmada Therapeutics Key News & Latest Developments
7.8 BioCrea GmbH
7.8.1 BioCrea GmbH Company Summary
7.8.2 BioCrea GmbH Business Overview
7.8.3 BioCrea GmbH Glutamate Antagonist Major Product Offerings
7.8.4 BioCrea GmbH Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.8.5 BioCrea GmbH Key News & Latest Developments
7.9 Cerecor Inc.
7.9.1 Cerecor Inc. Company Summary
7.9.2 Cerecor Inc. Business Overview
7.9.3 Cerecor Inc. Glutamate Antagonist Major Product Offerings
7.9.4 Cerecor Inc. Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.9.5 Cerecor Inc. Key News & Latest Developments
7.10 NeurOp Inc.
7.10.1 NeurOp Inc. Company Summary
7.10.2 NeurOp Inc. Business Overview
7.10.3 NeurOp Inc. Glutamate Antagonist Major Product Offerings
7.10.4 NeurOp Inc. Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.10.5 NeurOp Inc. Key News & Latest Developments
7.11 UCB SA
7.11.1 UCB SA Company Summary
7.11.2 UCB SA Glutamate Antagonist Business Overview
7.11.3 UCB SA Glutamate Antagonist Major Product Offerings
7.11.4 UCB SA Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.11.5 UCB SA Key News & Latest Developments
7.12 Novartis AG
7.12.1 Novartis AG Company Summary
7.12.2 Novartis AG Glutamate Antagonist Business Overview
7.12.3 Novartis AG Glutamate Antagonist Major Product Offerings
7.12.4 Novartis AG Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.12.5 Novartis AG Key News & Latest Developments
7.13 Luc Therapeutics Inc.
7.13.1 Luc Therapeutics Inc. Company Summary
7.13.2 Luc Therapeutics Inc. Glutamate Antagonist Business Overview
7.13.3 Luc Therapeutics Inc. Glutamate Antagonist Major Product Offerings
7.13.4 Luc Therapeutics Inc. Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.13.5 Luc Therapeutics Inc. Key News & Latest Developments
7.14 Evotec AG
7.14.1 Evotec AG Company Summary
7.14.2 Evotec AG Business Overview
7.14.3 Evotec AG Glutamate Antagonist Major Product Offerings
7.14.4 Evotec AG Glutamate Antagonist Sales and Revenue in Global (2018-2023)
7.14.5 Evotec AG Key News & Latest Developments
8 Global Glutamate Antagonist Production Capacity, Analysis
8.1 Global Glutamate Antagonist Production Capacity, 2018-2029
8.2 Glutamate Antagonist Production Capacity of Key Manufacturers in Global Market
8.3 Global Glutamate Antagonist Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Glutamate Antagonist Supply Chain Analysis
10.1 Glutamate Antagonist Industry Value Chain
10.2 Glutamate Antagonist Upstream Market
10.3 Glutamate Antagonist Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Glutamate Antagonist Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ グルタミン酸拮抗薬の世界市場見通し2023年-2029年(Glutamate Antagonist Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • ベース編集技術のグローバル市場展望 2023年-2029年：DNA塩基編集、RNA塩基編集
  • 残留グルタミン酸ナトリウムのグローバル市場展望 2023年-2029年：粗MSG残渣、精製MSG残渣
  • アンドロゲン拮抗薬の世界市場見通し2023年-2029年
  • 神経学デジタル医薬品の世界市場見通し2023年-2029年
  • 性ホルモン拮抗薬の世界市場見通し2023年-2029年